CN106618818A - Woven vascular drug stent - Google Patents

Woven vascular drug stent Download PDF

Info

Publication number
CN106618818A
CN106618818A CN201710064756.6A CN201710064756A CN106618818A CN 106618818 A CN106618818 A CN 106618818A CN 201710064756 A CN201710064756 A CN 201710064756A CN 106618818 A CN106618818 A CN 106618818A
Authority
CN
China
Prior art keywords
top layer
medicine
blood vessel
braided support
limited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710064756.6A
Other languages
Chinese (zh)
Inventor
周奇
吴常生
张忠民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou Leo Medical Co Ltd
Original Assignee
Changzhou Leo Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changzhou Leo Medical Co Ltd filed Critical Changzhou Leo Medical Co Ltd
Priority to CN201710064756.6A priority Critical patent/CN106618818A/en
Publication of CN106618818A publication Critical patent/CN106618818A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

The invention belongs to the field of medical apparatuses, and in particular relates to a vascular woven stent. The vascular woven stent comprises a woven stent main body and a coating, wherein the woven stent main body is constituted by metal wires having a shape memory function; and the coating comprises a drug coating bottom course and a protective top course. The vascular woven stent provided by the invention, by combining the woven stent, can effectively relieve coating falling, so that an acute thrombosis risk is reduced, stimulation to vascular walls and blood vessels is relieved, an occurrence rate of vascular restenosis is reduced, thrombogenesis is relieved, influence of patients' complications to the drug coating is relieved, and finally, product's effectiveness is improved.

Description

A kind of braided blood vessel drug stent
Technical field
The invention belongs to medical instruments field, and in particular to a kind of blood vessel braided support, especially one kind can reduce acute Thrombosis, vascular restenosiss, the blood vessel braided support of blood vessel advanced thrombus incidence rate can be reduced.
Background technology
In recent years, intravascular stent is widely used in treating arteria coronaria blood vessel, peripheral blood as a kind of human vas implant Pipe, intracranial vessel etc..For arteria coronaria blood vessel, at present frequently with 316L rustless steels, cochrome or platinum evanohm, by sacculus Dilating catheter is expanded to up to diseased region.And compared with arteria coronaria, peripheral blood vessel diameter is bigger, lesion region is longer, frequently with certainly Swollen support, to reach more preferable therapeutic effect.
For from swollen support, mainly there are cutting support and braided support at present.Through application for many years, cutting support can be with Stenosis occlusion section blood vessel is supported, blood vessel elasticity is reduced and is bounced back and moulding again, keep tube chamber blood flow unobstructed, it is also narrow again with preventing Narrow, but while also gradually expose some shortcomings, such as compliance is not enough, easy fracture, the problems such as thrombotic risk at a specified future date is high.And weave and prop up Frame is by the netted body of a silk or multi-filament braiding winding.The braided support of close mesh due to its good compliance, compared with Strong support force, good adherence quality, excellent fatigue resistance and its blood vessel minor impact is increasingly received publicity.
At present, it is rarely reported for the coating drug delivery technologies of self expandable braided support.It is substantial amounts of compared with bare mental stents Clinical effectiveness shows that drug stent can effectively suppress the hypertrophy of smooth muscle, significantly reduces stent restenosis and target vessel blood fortune Reconstruction rate, can make restenosis rate be reduced to 10% even lower level.
Due to the self expandable characteristic of Self-expanded stent, loading and release and the balloon expandable of traditional coronary artery bracket of the support Formula has the difference of essence.Generally, Self-expanded stent is directly loaded up as in delivery sheath, and in course of conveying by loading attachment In, sheath is released by conveyer device.Whole process is without the need for sacculus.
Self-extending type braided support due to defining numerous cross points between silk and silk, in support loading process, support quilt Stretching, length would generally elongated 3 times or so, the friction between silk and silk may produce certain damage to coating integrity, very May extremely cause the large area of coating flakes to come off, cause acute thrombus, blood vessel blockage is caused then, ultimately result in drug stent Failure, great risk is caused to patient.Therefore, how to ensure the coating integrity of braided support, improve final clinic Effectiveness is still the problem of urgent need to resolve.
Additionally, self-extending type braided support is usually used in peripheral blood vessel pathological changes.In actual clinical, patient is often accompanied by glycosuria The complication such as disease or hypertension.Clinical evidence shows, drug stent to vascular lesion complication with diabetes patient outcomes still not Significantly [JACC Cardiovasc Interv 2013;6:523–32；J Invasive Cardiol 2014;26(7):98-99 ].Stenosis rate is higher after diabeticss stenter to implant, and increased the risk of stent thrombosis（ 25%-80% ）[N Engl J Med. 2009;361:1045-1057；N Engl J Med. 2007;357:2001-2015].Therefore, self-extending type braiding medicine Support is also required to reduce impact of the complication to medication coat.
The content of the invention
In view of the deficiencies in the prior art, it is an object of the invention to develop a kind of blood vessel braided support, it can effectively be reduced Coating shedding, reduces acute thrombus risk, reduces the stimulation to blood vessel wall and blood vessel, reduces the incidence rate of vascular restenosiss, subtracts Few thrombosiss, reduce impact of the complication for patients to medication coat, the final effectiveness for improving product.
The blood vessel braided support that the present invention is provided, including braided support body and coating, the coating includes medication coat Bottom and protectiveness top layer.
Preferably, described braided support body selected from shape memory groups of metal filaments into.
Preferably, described braided support body is formed selected from one or more braiding.
Preferably, described medication coat bottom is made up of biodegradable polymer and active medicine.
Preferably, described biodegradable polymer is selected from the homopolymer of aliphatic hydroxyl carboxylic acid or one kind of copolymer Or it is various.
Preferably, it is described biodegradable polymer, including but not limited to polylactic acid, polyglycolic acid, polycaprolactone, poly- Homopolymer and its copolymer of anhydride etc..
Preferably, described active medicine includes anti-oxidation medicine, anticoagulants, anticancer class medicine, suppression blood vessel One or more in smooth muscle cell proliferation class medicine, anti-inflammatory drug or immune suppressant drug.
Preferably, described active medicine, including but not limited to rapamycin, paclitaxel, cilostazol, match chloropyridine, Triptolide, dexamethasone, estrogen, VEGF somatomedin, one or more of CD34.
Preferably, described protectiveness top layer includes top layer high molecular polymer, can be selectively added or be added without Top layer active medicine.
Preferably, described top layer high molecular polymer has water solublity, high ductibility.
Preferably, described high molecular polymer, including but not limited to Polyethylene Glycol, polyvinylpyrrolidone, acrylic acid, One or more of polyacrylamide etc..
Preferably, described top layer active medicine includes but is not limited to diabetes medicament or hypertension drug.
Preferably, described diabetes medicament include but is not limited to insulin and the like, sulfonylurea, biguanideses, Alpha-glucosidase inhibitor, thiazolidinedione spread out lived material, Drugs Promoting Insulin Secretion, Chinese patent medicine etc..
Preferably, to include but is not limited to diuretic, calcium antagonistss, beta receptor blocking agent, blood vessel tight for described hypertension drug Open plain converting enzyme inhibitor drugs（ACEI）, blood pressure lowering Chinese patent medicine etc..
Description of the drawings
In order to more clearly describe technical scheme, briefly introduce below in conjunction with accompanying drawing.It is clear that this A little accompanying drawings are only some specific embodiments that the application is recorded.The present invention includes but is not limited to these accompanying drawings.
Fig. 1 is the planar structure schematic diagram that the blood vessel braided support of the embodiment of the present invention launches vertically.
Fig. 2 is the medication coat schematic diagram in the braided wires section of the blood vessel braided support of the embodiment of the present invention.Wherein 001 Braided wires, 002 is medication coat bottom, and 003 is protectiveness top layer.
Specific embodiment
The present invention will be further illustrated by the following examples, but these embodiments are only exemplary, and its purpose exists It is of the invention in allowing those skilled in the art to understand, rather than limit the scope of the invention.Can also have except exception is implemented The change of other multi-forms, here without the need for being exhaustive to all of embodiment.Protection scope of the present invention will by right Book is asked to determine, it is all according to the substantive equivalence changes made of the invention or variation, all it is included within the scope of the present invention.
Embodiment one
Scaffolding thread choice of material niti-shaped memorial alloy, by metal wire knitted into support, structure is as shown in Figure 1.
Take 0.1g poly D, L-lactic acids（PDLLA, weight average molecular weight range is 30,000-140,000）, add at room temperature To the dissolving of 10ml n-propyl acetates, uniformly solution is prepared, be subsequently adding 0.1g rapamycin mix homogeneously, by the molten of configuration Liquid is accurately sprayed into rack surface, used as the medication coat bottom of support.Subsequently take 0.1g polyvinylpyrrolidones（PVP, weight Average molecular weight scope is 30,000-200,000）, 10ml water dissolutioies are added at room temperature, prepare uniformly solution, spraying To the above-mentioned rack surface containing medication coat bottom, as protectiveness top layer.Place a stent into vacuum drying oven drying, Jing rings Oxidative ethane sterilizing is stand-by, and coating structure state is as shown in Figure 2.
After the completion of support is loaded and discharged, dissolving in vivo disappears the polyvinylpyrrolidone that the present embodiment is used Afterwards, medication coat plays a role.Poly- D, Pfansteihl will complete degraded after the function of completing drug release in 2 years.
Embodiment two
Scaffolding thread material is same as Example 1, and by metal wire knitted into support, structure is as shown in Figure 1.
Take 0.1g Poly(D,L-lactide-co-glycolides (poly (lactic-co-glycolic acid)（PLGA, divides equally again Son amount scope is 20,000-80,000), the dissolving of 10mL tetrahydrofurans is added at room temperature, prepares uniformly solution, then 0.1g paclitaxel mix homogeneously is added, the solution of configuration rack surface is accurately sprayed into into, as the medication coat bottom of support. Vacuum drying oven drying is placed a stent into, ethane via epoxyethane sterilizing is stand-by, and coating structure state is as shown in Figure 2.Subsequently take 0.1g Polyethylene Glycol（PEG, weight average molecular weight range is 10,000-30,000）, the dissolving of 10ml tetrahydrofurans is added at room temperature, Uniformly solution is prepared, the above-mentioned rack surface containing medication coat bottom is sprayed into, as protectiveness top layer.To prop up and mount In vacuum drying oven drying, ethane via epoxyethane sterilizing is stand-by.
The Polyethylene Glycol that the present embodiment is used is dissolved in vivo after disappearing, medicine after the completion of support is loaded and discharged Coating plays a role.The PLGA that the present embodiment is used will complete drop after the function of completing drug release in 9 months Solution.
Embodiment three
Scaffolding thread material is same as Example 1, and by metal wire knitted into support, structure is as shown in Figure 1.
Take 0.1g Poly(D,L-lactide-co-glycolides (poly (lactic-co-glycolic acid)（PLGA, divides equally again Son amount scope is 20,000-80,000), the dissolving of 10mL tetrahydrofurans is added at room temperature, prepares uniformly solution, then 0.1g paclitaxel mix homogeneously is added, the solution of configuration rack surface is accurately sprayed into into, as the medication coat bottom of support. Vacuum drying oven drying is placed a stent into, ethane via epoxyethane sterilizing is stand-by, and coating structure state is as shown in Figure 2.Subsequently take 0.1g Polyethylene Glycol（PEG, weight average molecular weight range is 10,000-30,000）, the dissolving of 10ml tetrahydrofurans is added at room temperature, Uniformly solution is prepared, 0.1g glibenclamides are subsequently adding, the above-mentioned rack surface containing medication coat bottom is sprayed into, is made For protectiveness top layer.Vacuum drying oven drying is placed a stent into, ethane via epoxyethane sterilizing is stand-by.
The Polyethylene Glycol that the present embodiment is used while dissolving in vivo, will be protected after the completion of support is loaded and discharged Out, local treatment diabetic patients position, subsequent medication coat plays a role glibenclamide drug release in shield property top layer. The PLGA that the present embodiment is used will complete degraded after the function of completing drug release in 9 months.
Beneficial effects of the present invention：
The present invention compared with prior art, with advantages below and effect：
Self expandable braided support is present invention employs, cutting support compliance deficiency, easy fracture is overcome, thrombotic risk at a specified future date is high The problems such as, provide reliable supporting role for continuous vessel；
Biodegradable coating technology is present invention employs, after medicine completes release, pharmaceutical carrier gradually completes degraded, it is to avoid by The risk of drug stent late vessel caused by the long-term existence of polymer.
The present invention increased protectiveness top layer on medication coat bottom, and during loading and release, top layer is due to it Hydrophilic, to wanting uncoated bottom to play protective effect, due to its hydrophilic after protective effect is completed, plays then The effect of medication coat, protects medication coat, improves the integrity of medication coat bottom, prevents because friction is led between silk and silk Cause simple medication coat to come off, improve the final effect of stent drug coating；
Protectiveness top layer in the present invention is hydrophilic macromolecule, good with histocompatibility, in addition can also packaging medicine coating The chip for coming off, greatly reduces acute thrombus risk.
In the present invention, the medicine of the treatment complication such as diabetes or hypertension can be increased in protectiveness top layer selectivity, On the one hand on the other hand impact of the complication to medication coat can be reduced, it is ensured that medication coat with local treatment complication Effective release.
The blood vessel braided support that the present invention is provided, had both improve the long-term reliability of braided support, also reduced acute blood The risk of bolt, while also solving the problems, such as in-stent restenosis and late vessel.
The explanation of above example is only intended to the core concept for helping understand the present invention.It should be pointed out that for this area Those of ordinary skill for, under the premise without departing from the principles of the invention, some improvement can also be carried out to the inventive method And modification, but these are improved and modification is also fallen in the range of the claims in the present invention are claimed.

Claims (14)

1. a kind of blood vessel braided support, including braided support body and coating, the coating includes medication coat bottom and protection Property top layer.
2. a kind of blood vessel braided support described in claim 1, wherein described braided support body is selected from having shape memory Groups of metal filaments into.
3. a kind of blood vessel braided support described in claim 1 or 2, wherein described braided support body is selected from one or more Silk braiding is formed.
4. a kind of blood vessel braided support described in claim 1, wherein described medication coat bottom is polymerized by biodegradable Thing and active medicine are constituted.
5. biodegradable polymer described in claim 4 selected from aliphatic hydroxyl carboxylic acid homopolymer or copolymer one kind or It is various.
6. claim 4, biodegradable polymer described in 5, it is characterised in that including but not limited to gather to polylactic acid, PVOH Acid, polycaprolactone, the homopolymer of condensing model and its copolymer etc..
7. active medicine described in claim 4, it is characterised in that including but not limited to anti-oxidation medicine, anticoagulants, anti- Cancer class medicine, the one kind or many suppressed in vascular smooth muscle cell curing class medicine, anti-inflammatory drug or immune suppressant drug Kind.
8. claim 4, active medicine described in 7, it is characterised in that described active medicine, including but not limited to rapamycin, Paclitaxel, cilostazol, match chloropyridine, Triptolide, dexamethasone, estrogen, VEGF somatomedin, one kind of CD34 or It is various.
9. a kind of blood vessel braided support described in claim 1, it is characterised in that described protectiveness top layer is that a kind of top layer is high Molecularly Imprinted Polymer, the polymer can be selectively added or be added without top layer active medicine.
10. a kind of top layer high molecular polymer described in claim 9, it is characterised in that the top layer high molecular polymer has water Dissolubility, high ductibility.
11. claim 9, the top layer high molecular polymer described in 10, it is characterised in that described high molecular polymer include but It is not limited to one or more of Polyethylene Glycol, polyvinylpyrrolidone, acrylic acid, polyacrylamide etc..
The top layer active medicine that can be selectively added described in 12. claim 9, it is characterised in that described top layer is lived Property medicine includes but is not limited to diabetes medicament or hypertension drug.
Top layer active medicine described in 13. claim 12, it is characterised in that described diabetes medicament includes but is not limited to pancreas Island element and the like, sulfonylurea, biguanideses, alpha-glucosidase inhibitor, thiazolidinedione spread out lived material, rush Insulin secretion agent, Chinese patent medicine etc..
Top layer active medicine described in 14. claim 12, it is characterised in that described hypertension drug includes but is not limited to profit Urine medicine, calcium antagonistss, beta receptor blocking agent, angiotensin converting enzyme inhibitor（ACEI）, blood pressure lowering Chinese patent medicine etc..
CN201710064756.6A 2017-02-05 2017-02-05 Woven vascular drug stent Pending CN106618818A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710064756.6A CN106618818A (en) 2017-02-05 2017-02-05 Woven vascular drug stent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710064756.6A CN106618818A (en) 2017-02-05 2017-02-05 Woven vascular drug stent

Publications (1)

Publication Number Publication Date
CN106618818A true CN106618818A (en) 2017-05-10

Family

ID=58845977

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710064756.6A Pending CN106618818A (en) 2017-02-05 2017-02-05 Woven vascular drug stent

Country Status (1)

Country Link
CN (1) CN106618818A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111110399A (en) * 2019-12-09 2020-05-08 先健科技(深圳)有限公司 Implantable device
CN112930202A (en) * 2018-08-24 2021-06-08 扩凡科技有限公司 Vascular device and method for producing a vascular device
WO2022060761A1 (en) * 2020-09-18 2022-03-24 Becton, Dickinson And Company Arterial Drug Eluting Device to Treat Diabetes With Targeted Delivery of Medication

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083257A (en) * 1995-11-01 2000-07-04 Biocompatibles Limited Braided stent
CN1678359A (en) * 2002-06-28 2005-10-05 科迪斯公司 Drug-eluting stents for treating vulnerable coronary plaques
US20050283224A1 (en) * 2004-06-22 2005-12-22 Scimed Life Systems, Inc. Implantable medical devices with antimicrobial and biodegradable matrices
CN201006050Y (en) * 2006-10-18 2008-01-16 北京乐普医疗器械有限公司 Biological degradable macromolecular medicament-carrying covering cardiovascular bracket
US20080172124A1 (en) * 2007-01-11 2008-07-17 Robert Lamar Bjork Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention
CN101279112A (en) * 2008-05-15 2008-10-08 哈尔滨工程大学 Intravascular stent with PLGA blend medicament eluting surface coating
CN201150578Y (en) * 2007-12-26 2008-11-19 上海康德莱企业发展集团有限公司 Blood vessel weaving stent
CN201404319Y (en) * 2009-04-02 2010-02-17 蔡文胜 Medicine slow-release support frame
CN105266934A (en) * 2015-09-17 2016-01-27 常州乐奥医疗科技有限公司 Woven vascular stent
CN106073957A (en) * 2016-06-20 2016-11-09 常州乐奥医疗科技股份有限公司 A kind of Novel weaved intravascular stent

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083257A (en) * 1995-11-01 2000-07-04 Biocompatibles Limited Braided stent
CN1678359A (en) * 2002-06-28 2005-10-05 科迪斯公司 Drug-eluting stents for treating vulnerable coronary plaques
US20050283224A1 (en) * 2004-06-22 2005-12-22 Scimed Life Systems, Inc. Implantable medical devices with antimicrobial and biodegradable matrices
CN201006050Y (en) * 2006-10-18 2008-01-16 北京乐普医疗器械有限公司 Biological degradable macromolecular medicament-carrying covering cardiovascular bracket
US20080172124A1 (en) * 2007-01-11 2008-07-17 Robert Lamar Bjork Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention
CN201150578Y (en) * 2007-12-26 2008-11-19 上海康德莱企业发展集团有限公司 Blood vessel weaving stent
CN101279112A (en) * 2008-05-15 2008-10-08 哈尔滨工程大学 Intravascular stent with PLGA blend medicament eluting surface coating
CN201404319Y (en) * 2009-04-02 2010-02-17 蔡文胜 Medicine slow-release support frame
CN105266934A (en) * 2015-09-17 2016-01-27 常州乐奥医疗科技有限公司 Woven vascular stent
CN106073957A (en) * 2016-06-20 2016-11-09 常州乐奥医疗科技股份有限公司 A kind of Novel weaved intravascular stent

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112930202A (en) * 2018-08-24 2021-06-08 扩凡科技有限公司 Vascular device and method for producing a vascular device
CN112930202B (en) * 2018-08-24 2023-10-27 扩凡科技有限公司 Vascular device and method for producing a vascular device
CN111110399A (en) * 2019-12-09 2020-05-08 先健科技(深圳)有限公司 Implantable device
CN111110399B (en) * 2019-12-09 2021-12-03 先健科技(深圳)有限公司 Implantable device
WO2022060761A1 (en) * 2020-09-18 2022-03-24 Becton, Dickinson And Company Arterial Drug Eluting Device to Treat Diabetes With Targeted Delivery of Medication

Similar Documents

Publication Publication Date Title
US8021678B2 (en) Implantable medical device with polymer coating in a surface area to volume ratio providing surface erosion characteristics
Muramatsu et al. Progress in treatment by percutaneous coronary intervention: the stent of the future
Sianos et al. Stent fracture and restenosis in the drug‐eluting stent era
EP2405953B1 (en) Articles and methods of treating vascular conditions
JP5329435B2 (en) Coronary stent with asymmetric drug release controlled coating
CN107049571A (en) A kind of vertebral artery stent and preparation method thereof
JP2005537044A (en) Method and apparatus for treating coronary vulnerable plaque using a drug eluting stent
CN102151185A (en) Biodegradable stent with laminated coatings
US20060204537A1 (en) Silicone blends and composites for drug delivery
CN106618818A (en) Woven vascular drug stent
KR101708748B1 (en) Spatiotemporal multicontrollable intelligent drug-eluting stent
US20200229954A1 (en) Bioabsorbable flow diverting scaffold
Lee et al. Novel bifurcation stents coated with bioabsorbable nanofibers with extended and controlled release of rosuvastatin and paclitaxel
Ang et al. Fundamentals of bioresorbable stents
CN106937895A (en) Overlay film frame and preparation method thereof
CN100435880C (en) Medicament elution interventional medical apparatus and preparing method thereof
KR102522542B1 (en) Drug-eluting stent
CN112263360A (en) In vivo drug eluting stent and preparation method thereof
CN106691645A (en) Vascular drug stent
CN101641059A (en) Intracoronary stent with asymmetric drug releasing controlled coating
US20100234934A1 (en) Balloon Deployable Coronary Stent
CN111388155A (en) Implantable stent system
RU2775427C1 (en) Drug-eluting stent and method for production thereof
Ang et al. National Heart Centre Singapore, Singapore, Duke-NUS Medical School, Singapore, Nanyang Technological University, Singapore
Claessen et al. Specialized Balloons in Percutaneous Coronary Intervention: Cutting, Scoring, Gliding, and Drug‐Eluting Balloons

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170510

WD01 Invention patent application deemed withdrawn after publication